Trials / Recruiting
RecruitingNCT05960955
Cadonilimab Combination With Chemotherapy With or Without AK117 in Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
Phase II Clinical Study of Cadonilimab Combination With Chemotherapy With or Without the Anti-CD47 Antibody AK117 Neoadjuvant/Adjuvant Therapy for Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 90 (estimated)
- Sponsor
- Akeso · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This trial is a Phase II study. All patients are resectable Gastric or Gastroesophageal Junction Adenocarcinoma, Eastern Cooperative Oncology Group (ECOG) performance status 0-1.The purpose of this study is to evaluate the efficacy and safety of cadonilimab combined with chemotherapy with or without AK117 neoadjuvantin treatment of resectable Gastric or Gastroesophageal Junction Adenocarcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cadonilimab | IV infusion,Specified dose on specified days |
| DRUG | AK117 | IV infusion,Specified dose on specified days |
| DRUG | Oxaliplatin | IV infusion,Specified dose on specified days |
| DRUG | Tegafur-gimeracil-oteracil potassium | Oral,Specified dose on specified days |
| DRUG | Docetaxel | IV infusion,Specified dose on specified days |
| DRUG | 5-Fluorouracil | IV infusion,Specified dose on specified days |
Timeline
- Start date
- 2023-11-13
- Primary completion
- 2024-11-30
- Completion
- 2027-11-30
- First posted
- 2023-07-27
- Last updated
- 2023-11-18
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05960955. Inclusion in this directory is not an endorsement.